grants_govPAR-25-070
Open
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
- Response deadline
- Jan 7, 2027 Due in 123 days
- Date posted
- Nov 18, 2024
- Source
- Open notice
Description
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.
Classifications
- NAICS93.393
Documents (1)
- DownloadPAR-25-070-Full-Announcement.htmltext/html422 B
Contacts
- grantsinfo@nih.gov301-402-2541
Similar contracts
- NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required)Due Sep 18, 2026
- Research Opportunities in Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)Due Jul 5, 2029
- Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 eSubmission Clinical Trial Optional)Due Sep 7, 2028
- Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)Due Sep 10, 2027
- Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)Due Oct 8, 2027
- Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)Due Nov 16, 2027